No new directional signal, this is a pre-scheduled 10b5-1 plan fill. The plan has been executing steadily since April 2026; this filing adds one more trade within the same program. Monitor for any unexpected acceleration outside the plan or filings by other insiders. The stock's 90% buy-rated analyst consensus offsets any concern from a routine planned sale.
PHVS drugs
PHVS drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 26 $34.01entry
- T+1 · 5mo ago +2.06%α +0.41% · $34.71
- T+5 · 4mo ago −0.44%α −2.61% · $33.86
- T+20 · 4mo ago −2.21%α −3.47% · $33.26
- T+60 · 8w ago +5.91%α +1.42% · $36.02
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Director/10%-owner Lu Peng filed a Form 144 notice to sell 15,000 common shares valued at approximately $499,350. The sale is part of a pre-arranged 10b5-1 plan, with recent plan sales in April, May, and June 2026 already executed. As a structured plan sale, this filing signals no new opportunistic insider conviction, it is a routine step within an existing sell program.
Key Facts
- Lu Peng filed Form 144 to sell 15,000 shares, estimated value ~$499,350.
- The sale is under a 10b5-1 trading plan adopted August 19, 2025.
- Plan sales have been ongoing: 7,001 shares on Apr 22, 100 on Apr 23, 3,733 on Apr 29, 15,000 on Apr 30, 14,166 on May 1, and 300 on Jun 18 at prices from ~$25 to ~$34.
- Morgan Stanley Smith Barney is the broker handling the planned sales.
- PHVS has $2.3B market cap with strong analyst consensus (90% bullish, 9 Strong Buy, 9 Buy, 2 Hold).
Financial Impact
~$499,350 in aggregate potential proceeds from 15,000 shares at ~$33.29 per share implied by filing
Risk Factors
- Multiple insiders or unplanned sales could shift sentiment, but this standalone 144 is low-risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-006503 |
| Document: 0001950047-26-006503-index.html | 0001950047-26-006503 |
| Document: 0001950047-26-006503.txt | 0001950047-26-006503 |
Track record
51 reports on PHVS
15 of 18 bullish or bearish reports moved the stock their way by T+5. Best: +23.73% at T+20 after the Sep 17, 2026 report. 17 of 19 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $33.19 Now $32.44 −2.26% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry $33.59 Now $32.44 +3.42% settles Nov 23
- Nov 12, 20264d ago Press Release Bullish 7/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
- Nov 12, 20264d ago 6-K Neutral 4/10 No price data
- Nov 12, 20264d ago Press Release Neutral 5/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
- Sep 25, 20267w ago Insider Cluster Bearish 6/10 Entry $32.02 to $31.19 Now $32.44 −1.31% ▲ +2.59% +2.37% vs SPY
- Sep 24, 20267w ago Insider Cluster Bearish 7/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
- Sep 24, 20267w ago Insider Cluster Bearish 5/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
- Sep 23, 20267w ago Insider Cluster Bearish 6/10 Entry $33.07 to $31.72 Now $32.44 +1.91% ▲ +4.08% +3.41% vs SPY
- Sep 21, 20268w ago Insider Cluster Bearish 5/10 Entry $36.02 to $31.91 Now $32.44 +9.94% ▲ +11.41% +10.39% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers